Pierre Miniou News Today

InFlectis BioScience granted Orphan Drug Designation for IFB-088 (icerguastat), a clinical stage treatment for Amyotrophic Lateral Sclerosis

InFlectis BioScience Receives Approval from French Regulatory Authority to Conduct a Phase 2 Clinical Trial for IFB-088 (Icerguastat) for the Treatment of

(1) Milan, Italy and Nantes, France--(Newsfile Corp. - April 29, 2021) - A new study shows indications that Amyotrophic Lateral Sclerosis (ALS) may be treated with small molecules targeting the Integrated Stress Response (ISR). ALS patients showed a diminished disease progression based on analysis of functional endpoints. The study was recently published in the journal Brain. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: A new stud...

Clinical Study Demonstrates Promising Results for Investigative ALS Treatment; InFlectis BioScience is Planning Phase 2 Trial of Next-Generation Therapy Reportable 30 Apr 2021, 01:16 GMT+10 Clinical Study Demonstrates Promising Results for Investigative ALS Treatment; InFlectis BioScience is Planning Phase 2 Trial of Next-Generation Therapy Milan, Italy, & Nantes, France -- April 29, 2021 -- A new study shows indications that Amyotrophic Lateral Sclerosis (ALS) may be treated with small molecul...